Protein Profiling of Rat Ventral Prostate following Chronic Finasteride Administration

IDENTIFICATION AND LOCALIZATION OF A NOVEL PUTATIVE ANDROGEN-REGULATED PROTEIN∗§

Corinne Cayatte‡§¶, Catherine Pons‡, Jean-Marie Guigonis∥, Jérôme Pizzol‡, Laetitia Elies§, Philippe Kennel§, David Rouquié§, Rémi Bars§, Bernard Rossi‡, and Michel Samson‡**

To better understand the effects of antiandrogens on the prostate, we investigated the changes in the proteome of rat ventral prostate (VP) following treatment with a well characterized 5α-reductase inhibitor, finasteride. Sprague-Dawley rats were treated daily by gavage with finasteride at 0, 1, 5, 25, and 125 mg/kg/day. Changes in plasma hormone levels as well as the weight and histology of sex accessory tissues were determined after 28 days of treatment and showed a dose-related decrease of VP weights together with a marked atrophy of the tissue visible at the macroscopic and microscopic levels. In addition, significant reductions in seminal vesicle and epididymis weights were noted. VP proteins were analyzed by two-dimensional gel electrophoresis: 37 proteins, mainly involved in protein synthesis, processing, and cellular trafficking and in metabolism, detoxification, and oxidative stress, were identified as modulated by finasteride. The prominent feature of this study is the demonstration of finasteride dose-dependent up-regulation of a protein similar to L-amino-acid oxidase 1 (Lao1). An up-regulation of this protein was also observed with the antiandrogen flutamide. Lao1 expression occurred as early as 48 h after antiandrogen administration and persisted throughout the treatment duration. Immunohistochemistry showed that this protein was only detectable in epithelial cells and secretory vesicles. Altogether these data point to a potential use of Lao1 to reveal antiandrogen-induced prostate injury. Molecular & Cellular Proteomics 5:2031–2043, 2006.

Prostate growth and homeostasis are controlled by androgens through their interaction with the nuclear androgen receptor (AR). This intranuclear receptor acts as a DNA-binding transcription factor, which regulates the expression of an array of target genes (1). Castration of young adult rats causes a reduction in testosterone, which induces a dramatic regression of prostate cell number as well as the secretory activity of the prostate (2). Such tissue damage can also be chemically induced by therapeutic drugs or by some environmental pollutants that exhibit antiandrogenic activity (3). Due to the widespread use of man-made chemicals, the identification of those that potentially interfere with reproductive functions has become a real public health issue. These so-called endocrine disruptors are thought to be responsible for sperm infertility in adult men (4) and for impairments of sex organ development during puberty in individuals that have been exposed to the chemical in utero (5).

Finasteride, a drug widely used in the treatment of alopecia and benign prostatic hyperplasia (6), acts on rat prostate through inhibition of the 5α-reductase (5αR) (7, 8), an enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). Both short (15 days) and long term (1–2 years) exposure of rats to this compound have already been shown to induce a marked decrease in intraprostatic DHT levels that is followed by a reduction of the ventral lobe weight. Moreover morphometric analyses revealed a significant decrease in absolute volume of both glandular epithelial and stromal compartments of rat prostate with a subsequent reduction in prostate secretions (9–11). It has also been demonstrated that rat prostate involution observed under finasteride treatment is partly due to apoptosis (11) and to a dramatic regression of prostate vascularization (12).

The 28-day toxicity study in the rat and its recent enhancement of the test guideline 407 designed by the Organisation for Economic Co-operation and Development (OECD guideline for testing of chemicals; adopted by the council on July, 27 1995; Repeated Dose 28-day Oral Toxicity Study in Rats) (13, 14) has recently been proposed for the detection of endocrine-mediated effects from chemicals such as finasteride. Thus, the following study based on the OECD 28-day
studies was designed to investigate the molecular events associated with the atrophy of VP induced by a chronic exposure to the 5αR inhibitor finasteride. Although the effects of androgen deprivation on prostate morphology and physiology are well documented, the underlying molecular mechanisms remain unclear. Many recent studies have attempted to explain these processes through transcriptome analyses (15–17). However, as there are growing evidences that an increase in the transcriptional level is not necessarily correlated with an increase of the encoded protein (18), we decided to include a proteomics component to our study.

Under our experimental conditions, finasteride induced ventral prostate weight loss and atrophy and modified the expression level of 37 proteins as revealed by two-dimensional gel electrophoresis (2D-gel) pattern analyses. These analyses highlighted a dose-dependent up-regulation of a protein similar to Lao1 that is specifically expressed by prostate epithelial cells. Under treatment with an antiandrogen (flutamide) (19), we confirmed that a dose-dependent high level of expression of Lao1 was achieved at early time points (48 h) and persisted after 28 days of treatment. Because of the production of H2O2 by Lao1 it is conceivable that the resulting oxidative stress may contribute to the deleterious effect of the antiandrogens.

**EXPERIMENTAL PROCEDURES**

**Toxicology Study**

**Chemicals and Dose Preparations**

Finasteride (Chemical Abstracts Service number 98319-26-7, APIN Chemicals Ltd., Oxfordshire, UK) and flutamide (Chemical Abstracts Service number 13311-84-7, Sigma) were stored in an air-tight, light-resistant container at room temperature. The dosing formulations of finasteride and flutamide were prepared at the required concentrations in aqueous 0.5% (w/v) methylcellulose weekly and every other week, respectively, and stored at 4 °C.

**Animals**

All animal work was performed at Bayer CropScience (Sophia-Antipolis, France) in accordance to the French laws for animal experimentation. The protocol, in-life phase, raw data, and study report were performed according to standard operating procedures that ensures a similar body weight distribution among groups. The animals received by gavage a single daily dose of either the vehicle alone (0.5% aqueous methylcellulose) as control or the test sub-
stances for 28 days. Based on previous data generated at Bayer CropScience Sophia-Antipolis, 2 the dose levels were selected as follows: finasteride was given at 1, 5, 25, or 125 mg/kg/day, and flutamide was given at 6, 30, or 150 mg/kg/day. A dosing volume of 5 ml/kg of body weight was used for the duration of the study and adjusted at weekly intervals according to individual body weights.

**Short Term Treatment**—After an overnight fast, randomized groups of six rats per experimental condition were given by gavage a single bolus of the vehicle alone (0.5% aqueous methylcellulose) as control or flutamide at a dose level of 150 mg/kg using a dosing volume of 5 ml/kg of body weight.

**Animal Euthanasia**—All animals were sacrificed in a randomized fashion by exsanguination under deep anesthesia (pentobarbital, intraperitoneal injection of 60 mg/kg of body weight) between 8:00 a.m. and 12:00 a.m. either 24 or 48 h after dosing (short term treatment) or 24 h after the last dose (day 29, long term treatment).

**Hormone Analysis**

At sacrifice, blood samples from the abdominal aorta were collected in lithium heparin-containing tubes, and the resulting plasma samples were kept frozen (−20 °C) until the determination of triiodothyronine (T3), thyronine (T4), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and testosterone (T) levels could be performed using specific radioimmunoassay kits (Amersham Biosciences for TSH and LH and Beckman Coulter, Villepinte, Paris, France for T3, T4, and T).

**Postmortem Examination and Organ Weights**

The following organs were collected and weighed: brain, kidney, liver, dorsolateral and ventral prostate, testes (individually), thyroid gland (with parathyroid gland), penis glans, seminal vesicles (with coagulating gland), adrenal gland, Cowper gland, levator ani and bulbocavernous muscles, and epididymides (individually). VP was halved: one half was preserved in 10% neutral buffered formalin for histological analysis, and the other half was weighed, snap frozen in liquid nitrogen, and stored frozen below −70 °C until proteome analysis.

**Statistical Analyses**

Statistical analyses on body and organ weights and hormonal parameters were calculated for each group, and Bartlett’s test was performed to compare the homogeneity of group variances. If Bartlett’s test was not significant (α = 5%), means were compared using the analysis of variance (ANOVA). If the ANOVA was significant (α = 5%), means of the exposed groups were compared with the mean of the control group using Dunnett’s test.

For body and organ weights, if Bartlett’s test was significant (α = 5%), group means were compared using the non-parametric Kruskal-Wallis test. If the latter was not significant, the group means were considered to be homogeneous, and no further analysis was performed. If the Kruskal-Wallis test was significant (α = 5%), means of the exposed groups were compared with the mean of the control group using Dunn’s test.

For the hormonal parameters, if Bartlett’s test was significant (α = 5%), data were transformed using the log transformation, if Bartlett’s test on log-transformed data was not significant, means were compared using the ANOVA on log-transformed data. If the ANOVA on log-transformed data was not significant (α = 5%), the group means were considered homogeneous, and no further analysis was performed. If the ANOVA on log-transformed data was significant (α =

---

2 P. Kennel and R. Bars, unpublished data.
5%), means of the exposed groups were compared with the mean of the control group using Dunnett’s test on log-transformed data. If Bartlett’s test on log-transformed data was significant, group means were compared using the non-parametric Kruskal-Wallis test. If the latter was not significant, the group means were considered to be homogeneous, and no further analysis was performed. If the Kruskal-Wallis test was significant (α = 5%), means of the exposed groups were compared with the mean of the control group using Dunn’s test.

All the statistical tests were two-sided tests. Group means were compared at α level 5 and 1%. Statistical analyses were performed using the software PathTox System Version 4.2.2 (Xybion Corp., Cedar Knolls, NJ).

Histopathology
Formalin-fixed VP samples were embedded in paraffin wax. Histological sections (5 μm) were stained with eosin and hematoxylin for microscopic examination.

Immunohistochemistry
Histological sections (5 μm) were immunohistochemically stained using antibodies against Ki-67 (reference 550609, BD Pharmingen) according to the manufacturer’s instructions and using an autostainer, Discovery XT system (Ventana Medical Systems, Illkirch, France). Cell counting was done using Morpho Expert (Explora Nova, La Rochelle, France), and at least 1000 epithelial cells were counted for each control and each treated animal (finasteride, 125 mg/kg/day). The indices of Ki-67-positive cells are expressed as a percentage of the total number of cells counted. Data statistical analysis was performed using Pearson’s χ² test with Yates’ continuity correction.

Localization of Laco1 expression was investigated on 5-μm sections of VP of control and finasteride-treated rats (25 mg/kg/day) stained according to the manufacturer’s protocol number 38 (autostainer Discovery XT system, Ventana Medical Systems) with an anti-Laco antibody (Nordic Immunological Laboratories, Tilburg, The Netherlands) incubated for 60 min at 20 μg/ml.

Proteome Analysis
Sample Preparation
Frozen VPs were homogenized in rehydration buffer (RH) containing 7 M urea, 2 M thiourea, 4% CHAPS (electrophoretic grade, Sigma) using a Dounce homogenizer followed by a Tenbroeck homogenizer. After centrifugation (30 min, 22,000 × g, 15 °C), the protein concentration of the supernatant was determined using DCTM protein assay (Bio-Rad). Both extracts were kept frozen at -80 °C until used.

One-dimensional Gel Electrophoresis
Proteins solubilized in RH were adjusted to 3% SDS (w/v), supplemented with 5% β-mercaptoethanol (v/v), and 0.05% bromphenol blue (w/v) and incubated at 37 °C for 10 min prior to electrophoresis. RH-insoluble material in SDS-containing buffer was supplemented with 5% β-mercaptoethanol (v/v) and 0.05% bromphenol blue (w/v) and boiled for 5 min. SDS-PAGE was performed according to Laemmli (20): proteins (75 μg/lane) were separated on 1.5-mm-thick slab gels using a 3% acrylamide stacking gel and a 5–15% acrylamide linear gradient as resolving gel. Gels were run overnight at constant current (8 mA/gel). Proteins were then transferred on PVDF membrane as described below.

Two-dimensional Gel Electrophoresis and Protein Staining
Using a cup-loading system (Bio-Rad), 500 μg of each lysate were supplemented with 100 mM 2-hydroxyethyl disulfide (reference 373890250, Acros Organics, Geel, Belgium) (21). The samples were loaded onto IPG ReadyStrips™ pH 3–10, pH 3–6, pH 5–8, or pH 7–10 (17 cm, linear gradient, Bio-Rad) and rehydrated with 300 μl of RH supplemented with 100 mM 2-hydroxyethyl disulfide (8 h of passive rehydration at 20 °C). Isoelectric focusing on the Protein IEF cell from Bio-Rad was carried out as follows: 15 min at 250 V, a slow (15-h) voltage ramping to 10,000 V, and a final step at 10,000 V up to 300,000 V-h. Immediately after focusing, IPG strips were wrapped in plastic trays (rehydration trays, Bio-Rad) and stored at -80 °C. Prior to SDS-PAGE, proteins in the IPG were reduced with 130 mM DTT solubilized in 1.5 M Tris, pH 8.8, containing 4% SDS and 30% glycerol for 15 min and alkylated with 130 mM iodoacetamide solubilized in 1.5 M Tris, pH 8.8, containing 4% SDS and 30% glycerol for 20 min, and finally strips were equilibrated in 4% SDS, 30% glycerol, 1 M Tris, pH 6.8, for 60 min. The second dimension separation was run overnight at room temperature on a 1-mm-thick 10% polyacrylamide gel at a constant voltage up to 1300 V-h (Protean XL cell). Immediately after electrophoresis, gels were fixed in 40% ethanol, 3% phosphoric acid for 2 h, rinsed with deionized water three times for 30 min, and then stained for 16 h with Bio-Safe Coomassie stain (Bio-Rad). Gels were scanned using a GS-800 calibrated densitometer (Bio-Rad).

Protein patterns were compared using PD-Quest imaging system (Version 7.1, Bio-Rad): expression levels of the proteins were quantified by analyzing the intensity of each spot. After normalization (based on total quantity of valid spots on the gels), statistical differences in expression between control and treated animals were assessed through the Mann-Whitney test. Spots with a p value <0.05 were considered to be statistically significant and were subsequently treated for identification by mass spectrometry.

In-gel Tryptic Digestion and Protein Identification by Mass Spectrometry
The protein spots of interest were manually excised from the 2D-gel and destained with 50% acetonitrile in 25 mM ammonium bicarbonate. Gel pieces were crushed in an Eppendorf tube, dehydrated with acetonitrile for 5 min, and vacuum-dried. Gel pieces were then rehydrated with 15 μl of 25 mM ammonium bicarbonate, 10% acetonitrile supplemented with trypsin (5 ng/μl, reference V5111, Promega, Madison, WI) at 37 °C for 16 h. Afterward trypsic peptides were extracted by 15-min incubations consecutively in 5% formic acid, 50% acetonitrile, and 80% acetonitrile. Sonifications (7 min, 400 watts, Deltasonic) were also performed during incubations to facilitate peptide extraction. Extracts were pooled before being evaporated under vacuum, and dry peptide samples were redissolved in 5% formic acid, 20% methanol.

Mass spectra were recorded with a MALDI-TOF spectrometer (Voyager DE-PRO, PerSeptive Biosystems, Framingham, MA) set in positive reflectron mode. Samples were spotted on a thin layer of nitrocellulose (0.5 μl of a 5 mg/ml solution in acetone/isopropanol/acetatic acid (1:1.2, v/v/v)) and then overlaid with a-cyano-4-hydroxy-cinnamic acid (0.75 μl of a 10 mg/ml solution in 50% acetonitrile, 0.3% TFA). The TOF was measured using the following parameters: 20-kV accelerating voltage, 74% grid voltage, 0.002% guide wire voltage, 250-nS delay time, and 500 low mass gate. External calibra- tion was performed using angiotensin 1 (M + H⁺, 1296.68), adreno- corticotrophic hormone (clip 18–39, M + H⁺, 2465.18; and clip 7–38, M + H⁺, 3657.93) in the same series as the sample to analyze.
Rat Ventral Prostate Proteomics under Finasteride Treatment

**TABLE I**

Effects of finasteride on body weight and sex organ and accessory tissue weights

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Finasteride (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Body weight (g) at terminal sacrifice</td>
<td>387 ± 18</td>
<td>383 ± 30 (-1%)</td>
</tr>
<tr>
<td>Organ weight (g) (mean ± S.D.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventrall prostate</td>
<td>0.46 ± 0.12</td>
<td>0.27 ± 0.09 (-41%)</td>
</tr>
<tr>
<td>Dorsal prostate</td>
<td>0.14 ± 0.07</td>
<td>0.11 ± 0.05 (-21%)</td>
</tr>
<tr>
<td>Seminal vesicles</td>
<td>1.24 ± 0.41</td>
<td>0.73 ± 0.24 (-41%)</td>
</tr>
<tr>
<td>Cowper glands</td>
<td>0.08 ± 0.01</td>
<td>0.056 ± 0.01 (-30%)</td>
</tr>
<tr>
<td>Right epididymis</td>
<td>0.50 ± 0.06</td>
<td>0.48 ± 0.07 (-4%)</td>
</tr>
<tr>
<td>Left epididymis</td>
<td>0.48 ± 0.05</td>
<td>0.46 ± 0.05 (-4%)</td>
</tr>
<tr>
<td>LABC muscle</td>
<td>0.70 ± 0.08</td>
<td>0.64 ± 0.08 (-9%)</td>
</tr>
</tbody>
</table>

* p < 0.05; n = 6.

**RESULTS**

Finasteride, a model compound for DHT withdrawal, was administered daily by gavage to young adult male Sprague-Dawley rats at different dose levels (0, 1, 5, 25, and 125 mg/kg/day). After 28 days of treatment, hormone levels (LH, TSH, T3, T4, and T) were measured on blood samples, and reproductive tissues including VP were removed, weighed, and examined microscopically.

**Effects of Finasteride on Body Weight and Sex Organ Weight**—Treatment with finasteride did not induce any mortalities or clinical signs. No effect on food consumption was observed at any dose level (data not shown). A slight decrease in body weight gain was noted at 125 mg/kg/day (~11%, not statistically significant) when compared with the control group (Table I). Overall there was a dose-related decrease in most of the sex organ and accessory tissue weights, the difference being statistically significant at 25 and 125 mg/kg/day for VP, seminal vesicles, Cowper gland, and right muscle.
epididymis (Table I). Ventral prostate weights decreased by 54% \((p < 0.05)\) and 67% \((p < 0.01)\) at finasteride doses of 25 and 125 mg/kg/day, respectively. No effects were observed on the weight of other tissues.

**Effects of Finasteride on Hormone Levels**—At sacrifice, mean T circulating concentration was found to be markedly increased only at the highest dose of finasteride \((+435\%, p < 0.05)\) (Fig. 1A). No apparent differences between control and treated animals were observed for LH (Fig. 1B), T3, T4, or TSH levels (data not shown).

**Effects of Finasteride on Ventral Prostate Morphology and Epithelial Cell Proliferation**—VPs from control and treated rats were fixed, sectioned, stained, and examined microscopically. Histological examination revealed atrophy of VP mainly characterized by a general reduction in size without prominent morphological changes; albeit some epithelium shrinkage could be observed in glandular ducts at the highest dose of finasteride. The number of animals that exhibited atrophy of the VP increased with increasing concentration of finasteride administered (Fig. 2, A and B). To evaluate finasteride effects on epithelial cell proliferation, VP sections of control and treated rats (125 mg/kg/day) were stained with an antibody raised against Ki-67, a nuclear cell proliferation-associated antigen expressed in all active stages of the cell cycle. Ki-67-positive cell indices revealed a statistically significant \((p < 0.001)\) decrease of cell proliferation in treated rats (Fig. 2, C and D).

**Proteome Analysis of Ventral Prostates of Control and Treated Animals**—In an attempt to elucidate the processes leading to prostate atrophy and subsequent weight loss, proteome analysis was undertaken. Proteins extracted from the VPs of control and all finasteride-treated animals were separated by 2D-gel and stained with the mass spectrometry-compatible colloidal Coomassie Blue (22). This powerful technique (23) allowed the separation and detection of approximately 1000 spots per organ, distributed over the different pH gradients used in this study.

Representative Coomassie Blue-stained gels of VP proteins from control and finasteride (1 mg/kg/day)-treated rats are depicted in Fig. 3. Spots modulated by finasteride treatment
are indicated with an arrow and an identification number as allocated by PD-Quest software. Image analysis of electrophoretic patterns revealed that finasteride significantly modified the expression of 40 spots among which 37 were identified by mass spectrometry (MALDI-TOF and/or ESI-MS/MS). Spot identities, MOWSE (molecular weight search) scores, mean normalized intensity ratios of treated versus control rats, statistical parameters, and reference articles related to the genes already shown to be androgen-regulated are presented in Table II. Unidentified proteins are presented in Table III.

The identified proteins have roughly been classified in six groups according to their functions. The first group corresponds to 11 proteins, down-regulated in response to finasteride treatment, that are involved in protein synthesis, processing, and cellular trafficking: EeF1γ (transcription factor), aspartyl- and arginyl-tRNA synthase (polypeptide synthesis), α-mannosidase 2C1 and sialic acid synthase (post-translational modifications), a protein similar to coat protein γ-COP, two forms of β-COP subunits and clathrin (vesicular transport and secretion), and three secreted proteins (two forms of prostatic spermine-binding protein, which have been described to differ by their degree of glycosylation (24); a cystatin-related protein; and S3 glandular kallikrein).

The second group includes proteins involved in cellular

![Fig. 3. 2D-gel pattern of control and finasteride-treated rats (1 mg/kg/day). 500 μg of rat ventral prostate proteins were first separated by IEF on different immobilized pH gradients (pH 3–6, pH 5–8, and pH 7–10) and then by SDS-PAGE (10% acrylamide). Spots were visualized by Coomassie Blue staining. Representative 2D-gels from control and finasteride-treated (1 mg/kg/day) rats are presented. Numbered spots correspond to proteins exhibiting a modified expression level upon finasteride treatment (details on identifications are presented in Tables II and III).](image-url)
metabolism. Three proteins were down-regulated due to finasteride exposure (ATP synthase α chain, an enzyme of the mitochondrial respiratory chain; farnesyl diphosphate synthase, an enzyme required for cholesterol biosynthesis as well as protein prenylation; and fructose 6-phosphate 2-kinase/fructose-2,6-bisphosphatase, a modulator of glycolytic fluxes in extrahepatic tissues). Four proteins were up-regulated following finasteride treatment (three glycolytic enzymes, fruc-
Rat Ventral Prostate Proteomics under Finasteride Treatment

Table III

<table>
<thead>
<tr>
<th>Spot number</th>
<th>Score</th>
<th>Protein coverage</th>
<th>Accession number</th>
<th>R1</th>
<th>R5</th>
<th>R25</th>
<th>R125</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2807</td>
<td>6.44e+14</td>
<td>37</td>
<td>Unknown (protein for MGC:91679)</td>
<td>2.12a</td>
<td>2.32a</td>
<td>2.59a</td>
<td>0.59</td>
</tr>
<tr>
<td>7508</td>
<td>1.5e+5</td>
<td>21</td>
<td>Similar to Riken cDNA 1810074P20</td>
<td>0.48b</td>
<td>0.67b</td>
<td>0.41a</td>
<td>0.75</td>
</tr>
<tr>
<td>7523</td>
<td>1.5e+4</td>
<td>18</td>
<td>Similar to Riken cDNA 1810074P20</td>
<td>0.48a</td>
<td>0.57a</td>
<td>0.41a</td>
<td>0.71</td>
</tr>
</tbody>
</table>

\[a \neq 0.05, \quad b \neq 0.01.\]

Glucose-6-phosphate dehydrogenase, a pyruvate kinase, and transketolase, an enzyme involved in interconnection of glycolytic and pentose monophosphate shunt pathways.

The inhibition of DHT synthesis due to the inhibition of 5αR also resulted in the modulation of proteins involved in cell morphology and muscle contraction. Only ezrin, a protein that anchors actin to the plasma membrane, was down-regulated. Annexin II (a calcium-dependent, phospholipid- and membrane-binding protein), tubulin-α6 chain (a major constituent of microtubules), and tropomyosins 1α and 2β (muscle proteins of the I-band that inhibit contraction by blocking the interaction of actin and myosin) were up-regulated. Detoxification proteins were also affected by finasteride treatment, leading to a down-regulation of two aldehyde dehydrogenases (mitochondrial and cytosolic) and an up-regulation of glutathione S-transferase Yb-2.

A fifth group of proteins (mainly chaperones), related to oxidative stress, was also modulated. Two proteins located in endoplasmic reticulum, GRP 78 and disulfide isomerase A3, were down-regulated. All others in this group were up-regulated: heat shock protein (HSP) 60 (mitochondria), HSP 70-related protein APG-2, similar to heat shock cognate 71-kDa protein, and HSP 90-β (cytoplasm). Finally we found a multiphasic response for two proteins related to apoptosis: the mitochondrial precursor of the programmed cell death protein 8 and a protein similar to programmed cell death 6-interacting protein.

When expressed as the ratio treated/control (Table II), most of the observed variations appeared to be of low magnitude as already described for messenger RNA levels (Table II, see related references) with the exception of some proteins that were barely detectable either in control or stimulated conditions (possibly leading to overestimated treated/control ratios). Moreover, some proteins exhibited an aberrant behavior characterized by consistent biphasic (i.e. β-COP) or even multiphasic responses (i.e. similar to programmed cell death-interacting protein). Such a behavior has already been observed for a well-known androgen-regulated gene, prostatein C3, and still remains unexplained (2).

Finasteride Induces an Up-regulation of a Protein Similar to Lao1—An interesting effect of finasteride on the rat VP proteome was the significant up-regulation of a putative pro-oxidant protein similar to Lao1. Lao1 was detectable on the 2D-gels in basal conditions, although this protein was only weakly expressed (Fig. 4A). Under finasteride treatment, an up-regulation by 10-fold was observed at 1 mg/kg/day finasteride (in comparison with control value, \( p < 0.01 \)) and by 19-fold at 25 mg/kg/day (\( p < 0.01 \)). At the highest dose of finasteride, the increase in expression of Lao1 was slightly less pronounced (14-fold, \( p < 0.01 \)), but this might reflect the deleterious effects of finasteride on the prostate tissue at this dose (Fig. 4, A and B).

Such an induction was also obtained with flutamide, a competitive inhibitor of AR (Fig. 4C). The induction profile was comparable to that observed with finasteride, namely an up-regulation at 6 and 30 mg/kg/day (3- and 9-fold increase, respectively) and a less pronounced effect at the highest dose tested (150 mg/kg/day, 6-fold increase). It is noteworthy that at the highest dose we observed an even more deleterious effect on hormonal levels for flutamide than for finasteride (see Supplemental Fig. 1S and prostate tissue (see Supplemental Table IS and Supplemental Fig. 2S).

A kinetic study (Fig. 4D) revealed that a 14-fold increase in Lao1 expression could be observed as soon as 48 h after the administration of a single bolus (150 mg/kg) of flutamide. No effect could be detected at 24 h (data not shown).

Immunolocalization of Lao1-like Protein—To identify the nature of the cells expressing Lao1, VP sections of control and finasteride-treated rats (25 mg/kg/day) were labeled with a polyclonal antibody, which was raised against snake venom Lao (the only commercially available anti-Lao antibody). Prior to this treatment, the antibody was first evaluated by Western blot to determine its ability to recognize rat Lao1 as shown in Fig. 5A.

Immunohistochemistry was subsequently performed using the Lao antibody on control and finasteride-treated VP sections (Fig. 5B). Microscopic examination of control sections revealed a faint Lao1 expression restricted to the perinucleolar area facing the apical pole and to membrane-bound secretory vesicles of the epithelium. Finasteride led to an enhanced labeling of these epithelial compartments. In addition, Lao1 labeling was no longer restricted to foci as in controls
but was instead spread throughout the entire epithelium layer.

**Effect of Finasteride on Protein Tyrosine Phosphorylation**—
Lao has been shown to oxidize amino acids and produce hydrogen peroxide (25), a reactive oxygen species known to increase protein tyrosine phosphorylation through the inhibition of protein tyrosine phosphatases (26, 27). To assess whether the up-regulation of Lao1 induced by finasteride came with an increase in protein tyrosine phosphorylation, rat ventral prostate proteins were blotted and incubated with anti-phosphotyrosine antibodies. As shown on Fig. 6A2, protein tyrosine phosphorylation in the RH-soluble fraction increased (up to 75% above the basal value) in a dose-dependent manner with finasteride concentration. Phosphoproteins with molecular masses ranging from 25 to 130 kDa were roughly affected to the same extent. The pattern obtained with the RH-insoluble material (Fig. 6B2) was different with an

---

**Fig. 4. L-Amino-acid oxidase profile and intensity in control and finasteride- or flutamide-treated animals.** A, sections of individual 2D-gels (pH 3–10) from all control and 28-day finasteride-treated animals. Dashed circles indicate the position of Lao1. B, histogram of 28-day finasteride-treated versus control ratios of mean Lao1 intensities normalized with PD-Quest software (see “Experimental Procedures”). R1, R2, R3, and R4, groups treated at 1, 5, 25, and 125 mg/kg/day, respectively. **, statistically different from control value (p < 0.01). C, histogram of 28-day finasteride-treated versus control ratios of mean Lao1 intensities normalized with PD-Quest software (see “Experimental Procedures”). R1, R2, R3, and R4, groups treated at 1, 5, 25, and 125 mg/kg/day, respectively. Asterisks, statistically different from control value (*, p < 0.05; **, p < 0.01). D, sections of individual 2D-gels (pH 3–10) from control and 48-h flutamide-treated animals. Dashed circles indicate the position of Lao1.
increased tyrosine phosphorylation occurring mainly on high molecular mass proteins (80–170 kDa) as observed at 25 and 125 mg/kg/day (15 and 72%, respectively).

DISCUSSION

Consistent with the 28-day study of Shao et al. (2), treatment of young adult male rats with finasteride produced a dramatic decrease in VP weight. A significant reduction in seminal vesicle, epididymis, and Cowper gland weights was also observed as these organs are also partially dependent on DHT for their homeostasis (28). The VP weight loss was the consequence of a marked atrophy of the tissue (10, 11, 29), a phenomenon constantly associated to finasteride treatment, and a decrease of epithelial cell proliferation. No effect of caspase-3 cleavage, analyzed by immunoblotting (data not shown), could be detected indicating that at 28 days apoptosis is no longer responsible for prostate atrophy. This is in agreement with a previous study performed by Rittmaster et al. (11) that showed that apoptotic events induced by finasteride occurred in a window ranging from day 4 to day 14.

Prahalada et al. (9) showed that exposure to finasteride (160 mg/kg/day) for 15 days induced a not statistically significant up-regulation of plasma T level. In our model the increase of serum T level at day 28 of finasteride treatment (125 mg/kg/day) was statistically significant. The level of LH remained unchanged in our study and therefore could not account for the T up-regulation; it is likely that the increase in T level resulted from an accumulation of this hormone due to 5αR inhibition.

Similar results were obtained with flutamide except that this antiandrogen had a more deleterious effect on the organ, characterized by more important weight loss and tissue structure shrinkage at the highest dose tested. Unlike finasteride, flutamide increased LH plasma level in a dose-dependent manner.

Changes in hormone levels, weight, and histology of sex accessory tissues are standard parameters for evaluating the action of androgenic or antiandrogenic compounds in male rodents. Recent studies have suggested that the use of more sensitive methods, such as microarray analyses, are necessary to unravel the mode of action of these agents (17). To address this problem, we made use of the proteomics approach to investigate the mechanisms involved in VP atrophy following exposure of rats to finasteride. Despite a significant weight loss in VP, the protein profiles were well preserved across the various concentrations of finasteride tested. This is consistent with previous morphometric analyses, which showed that following finasteride treatment stromal and glandular tissues were affected to the same extent in rat VP, leaving the volume ratio between these tissues unmodified (9). It is worth mentioning that most of the effects on protein expression were observed from the lowest dose of finasteride even in animals exhibiting no VP atrophy (that is four of six animals, Fig. 2). This suggests that these effects are more likely due to DHT deprivation than to secondary effects of prostate atrophy.

Androgens have been described as being able to regulate
prostatic secretory functions as well as the expression of secreted proteins (15, 24, 30). In this regard we observed under DHT withdrawal a down-regulation of enzymes involved in protein glycosylation pathways (H9251 -mannosidase 2C1 and sialic acid synthase (31) and farnesyl diphosphate synthase (32)), of proteins involved in vesicular transport and secretion (clathrin (33), a protein similar to H9253 -COP, and two forms of H9252 -COP subunits (16)), and of secreted proteins (prostatic binding protein, cystatin-related protein, kallikreins, and pros-tatic spermine-binding protein). Kallikrein S3 has been related to human prostate-specific antigen (34).

Several groups have proposed that one of the earliest changes leading to VP shrinking following castration or finasteride treatment is a decrease of prostate vascularization (35, 36), which induces hypoxia, and an associated up-regulation of a typical hypoxic transcription factor, hypoxia-inducible factor-1α (37). Aldolase A, glyceraldehyde-3-phosphate dehydrogenase, and pyruvate kinase M were up-regulated upon finasteride treatment. These glycolytic enzymes have been shown to be up-regulated by hypoxia-inducible factor-1α (38). Hypoxia can also down-regulate the respiratory and metabolic activities of mitochondria: this could explain the decrease of mitochondrial aldehyde dehydrogenase and ATP synthase α chain expression.

In addition, HSP up-regulation in exposure to hypoxia has been well described in the heart, especially HSP 60 and HSP 70 chaperone families, which are involved in cellular protection (39). HSPs can also act as important modulators of apoptotic cell death (40). We observed a consistent up-regulation of different chaperones (mitochondrial HSP 60, a protein similar to heat shock cognate 71-kDa protein, heat shock 70-related protein APG-2 and HSP 90-β) in our study. The induction of HSP 70-related genes has already been described in VP following castration (41). The up-regulation of HSP 90 and the down-regulations of GRP 78 and disulfide isomerase A3 in our study are in agreement with a previous study of Rosen et al. (17).

GAPDH was also up-regulated due to DHT deprivation in the present study. Epner et al. (42) showed that GAPDH was up-regulated in rat VP epithelial cells and translocated to the nuclei following castration, raising the possibility that GAPDH could also play a role in DNA repair in addition to its role in glycolysis within the cytoplasm.

Nevertheless taken together all the above mentioned changes were of a rather modest amplitude. This is in contrast with the huge increase in the expression of a protein similar to Lao1 that we observed in the VP tissue administered with finasteride. To ascertain whether Lao1 expression was related to the VP tissue damages, we used an antiandrogen, flutamide. This drug mediates its effects via a different mechanism than finasteride by inhibiting the binding of DHT or testosterone on the AR. Interestingly the expression of Lao1 was also dramatically increased in VP tissue after flutamide treatment.

Lao is a member of the flavoenzymes, which transform L-amino acids into their corresponding α-keto acids with the concomitant release of hydrogen peroxide and ammonia. Lao is widely distributed in various organisms (bacterial, fungal, plant, snake, and mammalian species) with the snake venom enzyme being by far the best documented (25). Lao can induce cell death by apoptosis through H2O2-dependent and/or -independent pathways involving amino acid depletion (43, 44). Two new Lao family members were recently identified in mammalians: the interleukin-4-induced gene-1 isolated in mouse leukocytes (45) and a mouse milk Lao1 (46). They share a 41.4% identity and a 80.7% identity, respectively, with the rat Lao1 that we identified in rat VP. The latter presents a conserved key domain and residues involved in the binding of the FAD cofactor required for enzymatic activity.

Interestingly Tam et al. (47) have shown recently that androgen deprivation in castrated rats clearly induces oxidative

![Fig. 6. Effects of finasteride on protein tyrosine phosphorylation.](image-url)
stress in the regressing prostate epithelium and that testosterone replacement partially reduces this oxidative stress. The dramatic increase in Lao1 observed both in the cellular compartment and secretory vesicles from prostate epithelial cells of antiandrogen-treated rats could lead to oxidative stress through an overproduction of H$_2$O$_2$. This reactive oxygen species has been reported to increase the global pattern of cellular tyrosine phosphorylation by inhibiting the activity of protein tyrosine phosphatases (26, 27). Because it was virtually impossible to measure H$_2$O$_2$ content in frozen VP tissue, we thought it was of interest to use the level of tyrosine phosphorylation as an indirect reporter of H$_2$O$_2$ production. Finasteride treatment actually resulted in a dose-dependent increase of protein tyrosine phosphorylation both in RH-soluble and -insoluble fractions.

As shown in B cells by Takano et al. (48), oxidative stress induces the activation of multiple signaling pathways related to various cellular responses such as mitotic arrest, apoptosis, and necrosis, depending on the H$_2$O$_2$ concentrations. This might explain the aggravation of prostate tissue injury upon exposure to increasing doses of antiandrogen, a phenomenon that could be linked to overexpression of Lao1 and a subsequent enzymatic H$_2$O$_2$ production. In addition, we showed a decrease in VP epithelial cell proliferation under finasteride treatment that also could be a consequence of H$_2$O$_2$ accumulation.

In conclusion, the current proteome analysis of VP from finasteride-treated rats revealed an altered expression of an array of proteins reflecting an impairment of epithelial cell secretory functions and disruption of oxidative stress, detoxification, and apoptosis, which could be at least partially responsible for the prostatic atrophy observed following treatment. The prominent feature of this study remains the demonstration of the dose-dependent up-regulation of a protein similar to Lao1. The fact that this protein was increased in VP tissue as soon as 48 h after flutamide administration lends support to the notion that Lao1 could be considered as an early marker of antiandrogenic action on VP tissue.

Acknowledgment—We thank Aline Lorefice for valuable help for the immunohistochemistry on rat VP.

* This work was supported in part by INSERM and Bayer CropScience. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† The on-line version of this article (available at http://www.mcponline.org) contains supplemental material.

** To whom correspondence should be addressed. Tel.: 33-4-93-37-77-04; Fax: 33-4-93-81-94-56; E-mail: samson@unice.fr.

REFERENCES

23. Righetti, P. G., Castagna, A., Antonucci, F., Piubelli, C., Ceccon, D.,
Rat Ventral Prostate Proteomics under Finasteride Treatment


Steers, W. D. (2001) 5-


